For information, the company have announced that Tecentriq did not meet its primary endpoint during the Phase 3 trial and therefore they will no longer be pursuing a Marketing Authorisation Application in this indication at this time.
Therefore, NICE has decided to suspend this appraisal from its current work programme.
As this appraisal has been referred NICE will continue to monitor any development and will update interested parties as and when the situation changes.
| Status | Suspended |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 4052 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 21 June 2024 | Suspended. For information, the company have announced that Tecentriq did not meet its primary endpoint during the Phase 3 trial and therefore they will no longer be pursuing a Marketing Authorisation Application in this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties as and when the situation changes. |
| 02 November 2023 | Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during early July 2024 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately mid- September 2024. |
| 30 March 2023 | Following the changes to remove technical engagement as standard from appraisal timelines, the timelines for the appraisal of Atezolizumab for adjuvant treatment of high-risk locally advanced squamous cell head and neck cancer have been revised. It is anticipated that the appraisal will begin in early-March 2024 when we will write to you about how you can get involved. |
| 19 December 2022 | As you will be aware, the Department for Health & Social Care has asked NICE to conduct an appraisal of Atezolizumab for adjuvant treatment of high-risk locally advanced squamous cell head and neck cancer. Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin in mid-April 2024 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately late June 2024. |
For further information on our processes and methods, please see our CHTE processes and methods manual